Revisiting methotrexate and phototrexate Zinc15 library-based derivatives using deep learning in-silico drug design

Farhan Siddique1,2, Ahmar Anwaar3, Maryam Bashir2,4

  • 1School of Pharmaceutical Science and Technology, Tianjin University, Tianjin, China.

PubMed

Insights

Computational methods identified novel anticancer drug candidates by screening methotrexate derivatives against the dihydrofolate reductase target. Promising compounds show good oral bioavailability and low toxicity, warranting further experimental validation for cancer therapy.

Area of Science:

  • Computational chemistry and drug discovery
  • Medicinal chemistry and pharmacology

Background:

  • Cancer remains a leading cause of mortality globally, necessitating the development of new therapeutic agents.
  • Computational techniques offer a promising avenue for accelerating the discovery of novel anticancer drugs.

Purpose of the Study:

  • To perform QSAR-based virtual screening of methotrexate and phototrexate derivatives to identify novel inhibitors of dihydrofolate reductase (DHFR).
  • To predict the anticancer potential, ADMET properties, and toxicity of identified compounds using computational models.

Main Methods:

  • Quantitative Structure-Activity Relationship (QSAR) modeling using deep learning-based ADMET parameters and multiple linear regression (MPL).
  • Virtual screening of 271 methotrexate (MTX) and phototrexate (PTX) derivatives against the DHFR target.
  • Assessment of ADMET properties via message-passing neural network (MPNN) and density functional theory (DFT) calculations; molecular dynamics simulations for validation.

Main Results:

  • QSAR model achieved high predictive accuracy (LOO-CV Q2=0.77, R2=0.81).
  • Virtual screening identified eight top-hit compounds (09, 27, 41, 68, 74, 85, 99, 180) with significant predicted inhibitory activity (pIC50 5.85-7.20).
  • Selected compounds exhibit favorable oral drug potential (Log P 0.19-2.69, bioavailability 76.30%-78.46%) and low clinical toxicity, with compound 180 showing the least toxicity (8.30%).

Conclusions:

  • The identified lead compounds demonstrate superior or comparable anticancer potential to standard drugs MTX and PTX.
  • These compounds represent promising candidates for novel anticancer therapies, pending experimental validation.
  • Further in vitro and in vivo studies are recommended to confirm the inhibitory potential and efficacy of the identified hits.

Related Concept Videos

Therapeutic Drug Monitoring: Affecting Factors01:29

Therapeutic Drug Monitoring: Affecting Factors

Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring specific drug levels in a patient's blood or body tissues to manage and optimize therapy. TDM is crucial for drugs with narrow therapeutic windows, like warfarin and phenytoin, where incorrect doses can lead to treatment failure or severe side effects. This monitoring ensures the dosage administered is within a safe and effective range. The factors affecting therapeutic drug monitoring include:Patient-Specific Factors:a.
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...